Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial-Reference-Cited by-同舟云学术

Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial

Published:2019-03 Issue:3 Volume:4 Page:208-216
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Yoshikawa Takaki,Terashima Masanori,Mizusawa Junki,Nunobe Souya,Nishida Yasunori,Yamada Takanobu,Kaji Masahide,Fukushima Norimasa,Hato Shinji,Choda Yasuhiro,Yabusaki Hiroshi,Yoshida Kazuhiro,Ito Seiji,Takeno Atsushi,Yasuda Takashi,Kawachi Yasuyuki,Katayama Hiroshi,Fukuda Haruhiko,Boku Narikazu,Sano Takeshi,Sasako Mitsuru

Funder

AMED

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference16 articles.

1. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine;Sakuramoto;N Engl J Med,2007

2. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial;Bang;Lancet,2012

3. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer;Cunningham;N Engl J Med,2006

4. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction;Macdonald;N Engl J Med,2001

5. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial;Al-Batran;JAMA Oncol,2017

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of histologically poorly cohesive phenotype as a prognostic factor in patients with pStage II/III gastric cancer undergoing adjuvant chemotherapy;2024-08-18

2. The impact of preoperative skeletal muscle loss on the completion of S-1 adjuvant chemotherapy for gastric cancer;Surgery Today;2024-07-30

3. Reply to letter to the editor: “5-year follow-up results of a JCOG1104 (OPAS-1) phase III noninferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer”;Gastric Cancer;2024-07-10

4. Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023;ESMO Open;2024-07

5. Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer;Gastric Cancer;2024-04-11